超等抗体杂交瘤技巧(国外英文资料).docVIP

超级抗体杂交瘤技术(国外英文资料) The development of antibody drugs in the direction of higher targeted, lower repulsion, and the treatment of certain incurable diseases in clinical trials. Labuz j.f. the institute of cancer research in the fourth military medical university, says professor antibody drug although there are problems, but its theory has been fully confirmed, the market potential is tremendous. However, he also pointed out that domestic antibody-drug research and development companies should not blindly follow a new wave of antibody drugs, choosing a good starting point. Preferred starting point should be large-scale drug targeted screening, early indications of targeting have monopoly market to avoid product market big crash. Key support strength of enterprises, avoid again small miscellaneous antibody drug production enterprise of vicious competition in each other. Labuz j.f. said. Otherwise, it may recur in the 1990 s the development of biotech drugs in China, not only cant realize the dream of the revitalization of biotech drugs in China, on the contrary make antibody drug research and development into a passive situation of our country. However, ni jian, chairman and chief scientist of the early morning group drug development co., appears pessimistic. Antibody of generic drugs is a difficulty, there are a lot of drugs is very difficult to know at abroad antibodies of generic drugs do, structure, and can predict the number of antibody drug approval within five years rarely. NiJian, said foreign companies to do drug research and development, in order to protect the patent, the patent application, project declaration, published an article in the process, does not explicitly tell the structure of the final product. And that requires the domestic antibody generics company to figure it out. But some antibodies, from an amino acid sequencing perspective, make it difficult to measure both sides, and amino acid sequencing takes a lot of time and effort. For five years, M